YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation

Relapse is a limitation for the efficacy of the anaplastic lymphoma kinase (ALK)-inhibitor alectinib in ALK-rearranged lung cancer. Here, the authors show that YAP1 activation upon alectinib treatment leads to therapy resistance and that inhibiting both YAP1 and ALK leads to longer tumor remission i...

Full description

Bibliographic Details
Main Authors: Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Hironori Yoshida, Yuichi Sakamori, Hiroaki Wake, Mitsuyoshi Ueda, Young Hak Kim, Toyohiro Hirai
Format: Article
Language:English
Published: Nature Publishing Group 2020-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-13771-5
id doaj-3f80ddddea7640be87705e31f5e46a2a
record_format Article
spelling doaj-3f80ddddea7640be87705e31f5e46a2a2021-05-11T09:17:19ZengNature Publishing GroupNature Communications2041-17232020-01-0111111610.1038/s41467-019-13771-5YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulationTakahiro Tsuji0Hiroaki Ozasa1Wataru Aoki2Shunsuke Aburaya3Tomoko Yamamoto Funazo4Koh Furugaki5Yasushi Yoshimura6Masatoshi Yamazoe7Hitomi Ajimizu8Yuto Yasuda9Takashi Nomizo10Hironori Yoshida11Yuichi Sakamori12Hiroaki Wake13Mitsuyoshi Ueda14Young Hak Kim15Toyohiro Hirai16Department of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDivision of Applied Life Sciences, Graduate School of Agriculture, Kyoto UniversityDivision of Applied Life Sciences, Graduate School of Agriculture, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityProduct Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., LtdProduct Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., LtdDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDivision of System Neuroscience, Graduate School of Medicine, Kobe UniversityDivision of Applied Life Sciences, Graduate School of Agriculture, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityRelapse is a limitation for the efficacy of the anaplastic lymphoma kinase (ALK)-inhibitor alectinib in ALK-rearranged lung cancer. Here, the authors show that YAP1 activation upon alectinib treatment leads to therapy resistance and that inhibiting both YAP1 and ALK leads to longer tumor remission in mice.https://doi.org/10.1038/s41467-019-13771-5
collection DOAJ
language English
format Article
sources DOAJ
author Takahiro Tsuji
Hiroaki Ozasa
Wataru Aoki
Shunsuke Aburaya
Tomoko Yamamoto Funazo
Koh Furugaki
Yasushi Yoshimura
Masatoshi Yamazoe
Hitomi Ajimizu
Yuto Yasuda
Takashi Nomizo
Hironori Yoshida
Yuichi Sakamori
Hiroaki Wake
Mitsuyoshi Ueda
Young Hak Kim
Toyohiro Hirai
spellingShingle Takahiro Tsuji
Hiroaki Ozasa
Wataru Aoki
Shunsuke Aburaya
Tomoko Yamamoto Funazo
Koh Furugaki
Yasushi Yoshimura
Masatoshi Yamazoe
Hitomi Ajimizu
Yuto Yasuda
Takashi Nomizo
Hironori Yoshida
Yuichi Sakamori
Hiroaki Wake
Mitsuyoshi Ueda
Young Hak Kim
Toyohiro Hirai
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
Nature Communications
author_facet Takahiro Tsuji
Hiroaki Ozasa
Wataru Aoki
Shunsuke Aburaya
Tomoko Yamamoto Funazo
Koh Furugaki
Yasushi Yoshimura
Masatoshi Yamazoe
Hitomi Ajimizu
Yuto Yasuda
Takashi Nomizo
Hironori Yoshida
Yuichi Sakamori
Hiroaki Wake
Mitsuyoshi Ueda
Young Hak Kim
Toyohiro Hirai
author_sort Takahiro Tsuji
title YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
title_short YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
title_full YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
title_fullStr YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
title_full_unstemmed YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
title_sort yap1 mediates survival of alk-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
publisher Nature Publishing Group
series Nature Communications
issn 2041-1723
publishDate 2020-01-01
description Relapse is a limitation for the efficacy of the anaplastic lymphoma kinase (ALK)-inhibitor alectinib in ALK-rearranged lung cancer. Here, the authors show that YAP1 activation upon alectinib treatment leads to therapy resistance and that inhibiting both YAP1 and ALK leads to longer tumor remission in mice.
url https://doi.org/10.1038/s41467-019-13771-5
work_keys_str_mv AT takahirotsuji yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT hiroakiozasa yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT wataruaoki yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT shunsukeaburaya yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT tomokoyamamotofunazo yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT kohfurugaki yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT yasushiyoshimura yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT masatoshiyamazoe yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT hitomiajimizu yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT yutoyasuda yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT takashinomizo yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT hironoriyoshida yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT yuichisakamori yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT hiroakiwake yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT mitsuyoshiueda yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT younghakkim yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
AT toyohirohirai yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation
_version_ 1721450083176677376